Frontier Biotechnologies Inc. Stock Analysis 688221.SS

Frontier Biotechnologies, Inc. engages in the research, development, production, and sale of medicines. The company is headquartered in Nanjing, Jiangsu and currently employs 314 full-time employees. The company went IPO on 2020-10-28. The firm's products mainly include long-acting anti-human immunodeficiency virus (HIV) drugs, small nucleic acid drugs, and high-end generics. The long-acting anti-HIV drugs mainly include Aikoning. The small nucleic acid drugs mainly include FB7011, FB7013, and FB7014 and others. The high-end generics mainly include FB4001 and FB3002 and others. The firm's drugs are mainly used for the treatment of acquired immune deficiency syndrome (AIDS), abnormal blood lipids, and osteoporosis.